Obesity Affects Men and Women in Different Ways
On April 13, 2026, research published by ScienceDaily revealed something doctors had suspected for decades but had never been able to demonstrate with such clarity: obesity is not the same disease in men and women. The same extra pounds, the same elevated body mass index, the same clinical condition — but surprisingly different metabolic responses. Men accumulate dangerous visceral fat and overload the liver. Women develop chronic inflammation and elevated cholesterol. The human body, it turns out, gains weight in fundamentally distinct ways depending on sex.
And this changes everything we know about how to treat obesity.
What Happened
The research, released on April 13, 2026, analyzed the metabolic differences between obese men and women and reached conclusions that challenge the traditional approach of treating obesity as a uniform condition.
The main results were:
In obese men: The study identified a significantly greater tendency for accumulation of visceral abdominal fat — the type of fat that deposits around internal organs such as the liver, intestines, and pancreas. Additionally, obese men showed more pronounced signs of hepatic stress, indicating that the liver is being overloaded by excess fat and by the processing of substances released by visceral fat.
In obese women: The pattern was different. Obese women presented higher levels of systemic inflammation — a chronic immune response that affects multiple body systems — and higher cholesterol levels, particularly LDL ("bad" cholesterol). Fat in women tends to distribute more subcutaneously (beneath the skin) and less viscerally, but the inflammatory and lipid effects are more pronounced.
The central conclusion is that obesity provokes different metabolic responses depending on sex, which has direct implications for diagnosis, treatment, and prevention. Treating all obese patients the same way — with the same diets, the same medications, the same protocols — may be a suboptimal approach that ignores fundamental biological differences.
The research was reported by ScienceDaily on April 13, 2026 and generated immediate discussions in the medical community about the need for sex-differentiated treatment protocols.
Context and Background
Obesity is one of the greatest public health crises of the 21st century. According to the World Health Organization (WHO), more than 1 billion people worldwide live with obesity — a number that has tripled since 1975. In Brazil, data from the Ministry of Health indicate that more than 25% of the adult population is obese, with increasing rates across all age groups.
Historically, obesity was treated as a relatively simple condition: excess calories consumed relative to calories expended, resulting in fat accumulation. The prescribed solution was equally simple: eat less, exercise more. This simplistic view ignored the biological complexity of obesity — a condition influenced by genetics, hormones, gut microbiome, psychological factors, socioeconomic environment, and, as the 2026 research demonstrates, biological sex.
The idea that men and women accumulate fat in different ways is not new. Anyone can observe that men tend to gain weight in the abdominal region (the famous "beer belly"), while women tend to accumulate fat in the hips, thighs, and buttocks (the "pear" pattern). This difference in fat distribution is mediated by sex hormones: testosterone in men favors visceral accumulation, while estrogen in women directs fat to subcutaneous deposits.
What the 2026 research adds is the demonstration that these differences in fat distribution translate into distinct metabolic profiles — not just different appearance, but different diseases, different risks, and therefore the need for different treatments.
Previous studies had already suggested this direction. Epidemiological research showed that obese men have higher rates of non-alcoholic hepatic steatosis (fatty liver) and type 2 diabetes, while obese women have higher rates of autoimmune diseases and osteoarthritis. But the connection between fat distribution, metabolic profile, and sex-specific disease risk had never been demonstrated with the clarity of the April 2026 research.
The hormonal context is crucial for understanding these differences. Testosterone, predominant in men, promotes the accumulation of visceral fat — the fat that deposits inside the abdominal cavity, around the organs. This fat is metabolically active: it releases free fatty acids directly into the hepatic portal system (the vein that carries blood from the intestine to the liver), overloading the liver and contributing to insulin resistance.
Estrogen, predominant in premenopausal women, has a protective effect against visceral accumulation, directing fat to subcutaneous deposits. However, estrogen also modulates the immune system in complex ways, and excess adipose tissue in women appears to amplify inflammatory responses in ways that do not occur with the same intensity in men.
After menopause, when estrogen levels drop dramatically, women begin to accumulate more visceral fat and their risk profile approaches that of men — an observation that reinforces the central role of sex hormones in the metabolic differences of obesity.
Impact on the Population
The practical implications of this research are enormous, affecting everything from individual medical consultations to public health policies.
| Aspect | Obese Men | Obese Women | Clinical Implication |
|---|---|---|---|
| Fat distribution | Predominantly visceral (abdominal) | Predominantly subcutaneous (hips, thighs) | Different exams to assess risk |
| Liver risk | Greater hepatic stress | Lower direct hepatic stress | Men need more frequent liver monitoring |
| Inflammation | Moderate | Elevated (systemic) | Women may benefit from anti-inflammatory therapies |
| Cholesterol | Moderately elevated | Significantly elevated | Women need more aggressive lipid control |
| Cardiovascular risk | Via visceral fat and insulin resistance | Via chronic inflammation and dyslipidemia | Different mechanisms require different prevention |
| Response to diets | May vary | May vary | Sex-personalized diets may be more effective |
For the individual patient, the message is clear: obesity treatment should take biological sex into account as a determining factor in choosing therapeutic strategies.
For obese men, this means special attention to the liver. Regular liver function tests, abdominal ultrasound to assess steatosis, and in more severe cases, hepatic elastography to check for fibrosis. Exercise strategies that prioritize visceral fat reduction — such as moderate to high-intensity aerobic exercises — may be more effective than generic approaches.
For obese women, the priority should be controlling inflammation and cholesterol. Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) should be monitored regularly. Anti-inflammatory diets — rich in omega-3, fruits, vegetables, and whole grains — may have additional benefits beyond weight loss. And cholesterol control may require earlier pharmacological intervention than in men with the same BMI.
For the healthcare system, the research reinforces the need for differentiated protocols. Clinical guidelines that treat obesity as a uniform condition — prescribing the same exams, the same medications, and the same therapeutic targets for men and women — may be failing to identify specific risks and offer optimized treatments.
In Brazil, where the Unified Health System (SUS) serves millions of obese patients, implementing sex-differentiated protocols could significantly improve health outcomes. This would require training healthcare professionals, updating clinical guidelines, and possibly investing in additional diagnostic exams — but the return in terms of chronic disease prevention and reduced hospital costs would justify the investment.
The pharmaceutical industry is also paying attention. Obesity medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are among the best-selling in the world, but their clinical trials don't always analyze results separately by sex. The 2026 research suggests that this analysis should be mandatory, as the efficacy and side effects of these medications may differ significantly between men and women.
What Those Involved Are Saying
The researchers responsible for the study described the results as "a call to rethink the clinical approach to obesity." In statements to ScienceDaily, the authors emphasized that the differences found are not subtle — they are significant differences in fundamental metabolic markers that have direct implications for the risk of chronic diseases.
"We're not saying that obesity is less dangerous in one sex than the other," clarified one of the lead researchers. "We're saying it's dangerous in different ways, and that treatment should reflect those differences."
Endocrinologists who did not participate in the study reacted with cautious enthusiasm. "Clinically, we've always known that obese men and women present different profiles. But having solid data that quantifies these differences is extremely valuable for justifying differentiated treatment protocols," commented an endocrinologist from a university hospital.
Nutritionists highlighted the implications for diet prescription. "If obese women have more inflammation, anti-inflammatory diets should be prioritized. If obese men have more hepatic stress, diets that protect the liver — with less fructose, less alcohol, more antioxidants — make more sense," explained a clinical nutritionist.
Public health researchers pointed to the need for differentiated policies. "Obesity prevention campaigns that use the same message for men and women may be losing effectiveness. Men need to know that their belly is harming their liver. Women need to know that excess weight is causing chronic inflammation. Specific messages are more effective than generic ones," argued an epidemiologist.
Critics, however, warn of the risk of excessive simplification. "Biological sex is an important factor, but it's not the only one. Age, ethnicity, genetics, physical activity level, diet quality, and socioeconomic factors also influence the metabolic profile of obesity. We can't reduce everything to 'man vs. woman,'" pondered a metabolism researcher.
The study authors agree with this caveat but argue that biological sex is such a fundamental factor that ignoring it in obesity treatment is like ignoring the patient's age — technically possible, but clinically irresponsible.
The broader medical community has also noted that this research aligns with a growing movement toward sex-specific medicine across multiple specialties. Cardiology, for instance, has already recognized that heart attack symptoms differ between men and women, leading to updated diagnostic protocols. Pharmacology has documented that many drugs are metabolized differently depending on sex. The obesity findings add another compelling data point to the argument that biological sex should be a standard variable in all clinical research and treatment planning, not an afterthought.
Next Steps
The April 2026 research opens several fronts of investigation and action:
Sex-stratified clinical trials: The medical community is pushing for all clinical trials of obesity medications to analyze results separately by sex. This includes medications already on the market, such as semaglutide and tirzepatide, whose data can be reanalyzed to identify differences in efficacy and safety between men and women.
Development of specific biomarkers: Researchers are working to identify biomarkers that allow classifying obese patients into more precise metabolic subgroups than simply "man" or "woman." Combinations of inflammatory, hepatic, and lipid markers can create individualized profiles that guide treatment.
Update of clinical guidelines: Medical societies of endocrinology and obesity will likely revise their guidelines in the coming months to incorporate the evidence of metabolic differences by sex. This may include recommendations for specific exams, differentiated therapeutic targets, and adapted monitoring protocols.
Research on menopause and obesity: The menopausal transition, when estrogen levels drop, is a critical period for changes in the metabolic profile of obesity in women. Future research should investigate how obesity treatment should be adjusted during and after menopause.
Personalized medicine: In the long term, the trend is for obesity treatment to become increasingly personalized — taking into account not only sex but also the genetic profile, gut microbiome, hormonal history, and individual biomarkers of each patient. The 2026 research is an important step in this direction.
Medical education: Medical schools and residency programs will need to update their curricula to include the metabolic differences of obesity by sex. Doctors trained under the paradigm of "obesity is obesity, regardless of sex" will need professional updating.
Global health impact: The implications extend beyond wealthy nations with advanced healthcare systems. In developing countries where obesity rates are rising rapidly, understanding sex-specific metabolic differences could help allocate limited healthcare resources more effectively. Screening programs could be tailored to focus on liver health in men and inflammatory markers in women, potentially catching complications earlier and reducing the burden on already strained healthcare systems. International health organizations like the WHO are expected to review their obesity guidelines in light of this and similar research.
Closing
Obesity affects more than 1 billion people worldwide, but it doesn't affect everyone the same way. The April 2026 research demonstrated with clarity what biology has always suggested: men and women respond to excess weight in fundamentally different ways, with different risks, different mechanisms, and therefore the need for different treatments.
Men accumulate fat around organs and overload the liver. Women develop chronic inflammation and elevated cholesterol. The same disease, two distinct pathways of damage to the body.
The message for patients, doctors, and public policy makers is the same: in obesity, as in almost everything in medicine, the details matter. And biological sex is a detail too large to be ignored.
Brazil, with more than 50 million obese adults, has a unique opportunity to lead the implementation of sex-differentiated protocols. The SUS (Unified Health System), despite its budgetary limitations, possesses a reach that few health systems in the world can match — with more than 40,000 Basic Health Units spread across the entire national territory. If these units are trained to apply differentiated protocols, the impact on chronic disease prevention could be transformative.
The economic dimension is also relevant. Obesity costs the Brazilian health system more than R$3 billion per year in hospitalizations, bariatric surgeries, medications, and treatment of comorbidities. If sex-differentiated protocols can prevent even 10% of these complications by directing the right exams and treatments to each metabolic profile, the savings would be on the order of hundreds of millions of reais — resources that could be reinvested in prevention and nutrition education.
Another aspect that the research illuminates is the importance of the life stage at which treatment is initiated. For women, the peri-menopausal period — generally between ages 45 and 55 — represents a critical window where the metabolic profile of obesity changes dramatically with the decline in estrogen levels. Preventive interventions during this phase, including more frequent monitoring of inflammatory markers and lipid profiles, could prevent the cascade of cardiovascular complications that historically affects obese women after menopause.
For men, attention to the liver should begin earlier than current guidelines recommend. Epidemiological data suggest that obese men begin to develop signs of hepatic steatosis as early as their third decade of life — often before presenting any symptoms. Routine exams such as liver ultrasound and blood markers of liver function, if included in checkups for men with BMI above 30, could detect reversible damage before it becomes irreversible.
The discussion about nutrigenomics — the science that studies how nutrients interact with individual genes — also gains relevance with this research. If obesity manifests differently between sexes due to hormonal and genetic differences, it is reasonable to assume that the response to different types of diets also varies. Pilot studies already suggest that obese men respond better to diets with higher protein proportions and lower glycemic indexes, while obese women may benefit more from diets rich in omega-3 and anti-inflammatory compounds like curcumin and resveratrol. The personalization of nutrition based on sex, genetic profile, and individual biomarkers represents the next frontier of nutritional medicine.
